Medios AG Appoints Stefan Bauerreis as New Chief Financial Officer

The Supervisory Board of Medios AG has appointed Stefan Bauerreis as a member of the Executive Board and as the Company's new Chief Financial Officer, effective April 15, 2026. He succeeds Falk Neukirch, who will step down at his own request at the end of his regular term of office on April 30, 2026. This leadership transition occurs as Medios positions itself for continued growth in the specialty pharmaceutical sector, where the company has established itself as a leading provider of individualized medicine solutions across Europe.

With the appointment of Stefan Bauerreis, Medios gains an experienced finance expert with many years of international leadership experience in industry and at publicly traded companies. Among other roles, he served as Chief Financial Officer of the Stabilus Group and held various senior finance positions within the Schaeffler Group for more than two decades, including as CFO for the Europe region and CFO for Germany. Stefan Bauerreis possesses extensive expertise in Corporate Accounting, Controlling, Financing, and the transformation and management of international companies. This background is particularly relevant for Medios as it continues to expand its operations across multiple European markets.

Dr. Yann Samson, Chairman of the Supervisory Board of Medios AG, emphasized the strategic importance of this appointment, stating that with Stefan Bauerreis, the company is gaining a proven financial expert with extensive experience in internationally positioned SDAX and MDAX companies. He noted that Bauerreis combines operational excellence with strategic foresight and has repeatedly demonstrated throughout his career that he can successfully lead companies through periods of transformation. The Supervisory Board is convinced that he will provide important momentum for the future development of Medios, particularly as the company navigates the evolving landscape of specialty pharmaceuticals and individualized medicine.

Stefan Bauerreis expressed enthusiasm for his new role, stating that he looks forward to helping shape the future of Medios AG as part of the Executive Board. As CFO, he will contribute to further expanding the success of the Medios Group and its position as a leading Specialty Pharma company, both nationally and internationally, in the best interest of shareholders and employees. This appointment comes at a significant time for Medios, with several important events scheduled throughout the 2026 financial year, including the Metzler Small Cap Days in Frankfurt, the TP ICAP Midcap Conference in Paris, and the company's Capital Markets Day in September.

The leadership change occurs as Medios continues to strengthen its position in the specialty pharmaceutical market, where the company supports key partners in the supply chain with innovative solutions and intelligent services. More information about the company's approach to individualized medicine can be found at https://app.medios.group/en/individualizedmedicine. As Germany's first listed specialty pharmaceutical company, Medios AG maintains its shares on the regulated market of the Frankfurt Stock Exchange (Prime Standard) where they are included in the SDAX selection index. The company's corporate website at https://www.medios.group provides additional information about its operations and strategic direction.